STOCK TITAN
  1. Home
  2. News
  3. AVTX

Avalo Therapeutics Inc - AVTX STOCK NEWS

Welcome to our dedicated news page for Avalo Therapeutics (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avalo Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avalo Therapeutics's position in the market.

News
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Rhea-AI Summary
Avalo Therapeutics, Inc. (AVTX) appoints industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors. The appointments coincide with Avalo's acquisition of AVTX-009 and a $185 million private placement financing. The new board members bring extensive experience in biotech, finance, and clinical development to drive the development of AVTX-009 for autoimmune conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.31%
Tags
management
-
News
Avalo Reports 2023 Financial Results and Provides Business Updates
Rhea-AI Summary
Avalo Therapeutics, Inc. has acquired AVTX-009, a Phase-2 ready anti-IL-1β mAb, in March 2024. The company increased its cash position through private placement financing, securing up to $185 million, with an initial upfront investment of $115.6 million. Topline results from the Phase 2 trial of AVTX-009 in hidradenitis suppurativa are expected in 2026, with an anticipated cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.7%
Tags
earnings
-
News
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Rhea-AI Summary
Avalo Therapeutics, Inc. acquires Phase 2-ready anti-IL-1β mAb AVTX-009 through the acquisition of AlmataBio, Inc. They executed a private placement financing of up to $185 million, with an initial upfront investment of $115.6 million, extending cash runway into 2027. Topline results from a planned Phase 2 trial in hidradenitis suppurativa are expected in 2026. The company aims to develop AVTX-009 in HS and other chronic inflammatory indications, believing it has high success potential. The acquisition is expected to close on March 28, 2024, with a focus on treating inflammatory conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
357.89%
Tags
acquisition
News
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
Rhea-AI Summary
Avalo Therapeutics, Inc. (AVTX) announced a 1-for-240 reverse stock split of the Company’s common stock to increase the per share price and regain compliance with Nasdaq Capital Market listing requirements. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company. No fractional shares will be issued, and each stockholder who would otherwise be entitled to receive a fraction of a share of the Company’s common stock will instead receive one whole share of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23900%
Tags
none
-
News
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
Rhea-AI Summary
Company XYZ (XYZ) Adjourns Annual Meeting to December 20, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
none
-
News
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
Rhea-AI Summary
Avalo Therapeutics, Inc. (Nasdaq: AVTX) successfully eliminated $35 million debt, divested AVTX-800 series for potential $45 million milestone payments, and disclosed improved cash of approximately $10.2 million. The company's focus on immunology assets, including anti-LIGHT mAb and BTLA agonist fusion protein, positions it for future growth and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.09%
Tags
earnings
News
Avalo Completes Divestiture of AVTX-800 Series
Rhea-AI Summary
Avalo Therapeutics has completed the divestiture of its 800 Series programs to AUG Therapeutics. AUG paid an upfront payment of $150,000 and is obligated to make a contingent milestone payment of up to $45 million. Avalo's pipeline will now focus on immunology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.28%
Tags
none
-
News
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
Rhea-AI Summary
Avalo Therapeutics pays off $35 million debt to Horizon Technology Finance Corporation, signaling financial stability and paving the way for future growth and progress. Lead asset, quisovalimab, has demonstrated clinical proof of concept in inflammatory diseases. BTLA agonist fusion protein, AVTX-008, has potential to be a best-in-class molecule. Company well-positioned to pursue collaborations and bring innovative treatments to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.36%
Tags
none
-
News
Avalo Enters into Agreement to Divest AVTX-800 Series
Rhea-AI Summary
Avalo Therapeutics sells rights to 800 Series programs to AUG Therapeutics for upfront payment of $150,000 and potential milestone payment of $45 million. Transaction expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.88%
Tags
none
News
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Avalo Therapeutics CEO to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
conferences
Stock AVTX logo
Avalo Therapeutics Inc

Nasdaq:AVTX

AVTX Rankings

#5309 Ranked by Market Cap
#5541 Ranked by Stock Gains
N/A Ranked by Dividends

AVTX Stock Data

16.48M
919.32k
0.09%
6.33%
7.59%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Rockville

About AVTX

cerecor inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. we are a delaware corporation, organized in april 2011 in partnership with various laboratories and research institutes at johns hopkins medical institute ("jhmi"). cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. we acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.